A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE)
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE)
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).
Inclusion Criteria:
Exclusion Criteria:
CABA, 1023, Argentina
Capital Federal, C1116, Argentina
Capital Federal, C1120AAN, Argentina
Ciudad Autonoma Buenos Aires, C1061AAE, Argentina
Udine, Veneto 33100, Italy
Krakow, 31-501, Poland
Cheboksary, Mariy-El Republic 428000, Russia
Saint Petersburg, Sankt-Peterburg 197022, Russia
Irkutsk, 664033, Russia
Novosibirsk, 630096, Russia